Therefore, our preclinical study supports that FM could be a potent candidate drug for patients with JAK2-driven MPN with reduced adverse effects and better treatment outcomes than ruxolitinib and fedratinib. This evidence concerns the gene JAK2 and myeloproliferative disorder.